Document Detail

Safety of a non-viral plasmid-encoding dual isoforms of heypatocyte growth factor in critical limb ischemia patients: a phase I study.
MedLine Citation:
PMID:  21430785     Owner:  NLM     Status:  Publisher    
We aimed to evaluate in a phase I dose-escalation study, the safety of intramuscular injections of a novel non-viral plasmid DNA expressing two isoforms of human hepatocyte growth factor (HGF) (VM202) in patients with critical limb ischemia (CLI). In total, 12 patients with CLI and unsuitable for revascularization were consecutively assigned to increasing doses (2 to 16 mg) of VM202 administered into the ischemic calf muscle at days 1 and 15. Patients were evaluated for safety and tolerability, changes in ankle- and toe brachial index (ABI and TBI), and pain severity score using a visual analog scale (VAS) throughout a 12-month follow-up period. Median age was 72 years and 53% of the patients were male. VM202 was safe and well tolerated with no death during the 12-month follow-up. Median ABI and TBI significantly increased from 0.35 to 0.52 (P=0.005) and from 0.15 to 0.24 (P=0.01) at 12 months follow-up. Median VAS decreased from 57.5 to 16.0 mm at 6 months follow-up (P=0.03). In this first human clinical trial, VM202, which expresses two isoforms of human HGF, appear to be safe and well tolerated with encouraging clinical results and thus supports the performance of a phase II randomized controlled trial.Gene Therapy advance online publication, 24 March 2011; doi:10.1038/gt.2011.21.
T D Henry; A T Hirsch; J Goldman; Y L Wang; D L Lips; W D McMillan; S Duval; T A Biggs; H H Keo
Related Documents :
17475135 - Transfer of the flexor digitorum longus for the correction of lesser-toe deformities.
18711785 - Clinical results of early active mobilisation after flexor tendon repair.
20108185 - sports and activities after achilles tendon injury of the recreational athlete
2291315 - Use of omental pedicle for treatment of buerger's disease affecting the upper extremiti...
22014595 - Outcomes of grafted bulbar urethroplasty in men with class ii or iii obesity.
20922625 - Long-term outcomes following repair or replacement in degenerative mitral valve disease.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-3-24
Journal Detail:
Title:  Gene therapy     Volume:  -     ISSN:  1476-5462     ISO Abbreviation:  -     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-3-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9421525     Medline TA:  Gene Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, Minneapolis, MN, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Generation of dendritic cells and macrophages from human induced pluripotent stem cells aiming at ce...
Next Document:  Ovine pedomics: the first study of the ovine foot 16S rRNA-based microbiome.